Midi Health Company Overview & Business Model: An Independent Assessment

What Is Midi Health and How Does Its Business Model Work?

Midi Health is a telehealth company built specifically for women experiencing perimenopause and menopause. Founded in 2021, it connects patients with clinicians via video visits, prescribes FDA-approved hormone therapies and non-hormonal medications, and bills insurance directly rather than requiring out-of-pocket payment as the default. That insurance-first approach distinguishes it from several competitors.

The Insurance-First Architecture

Most direct-to-consumer hormone telehealth platforms operate on subscription or cash-pay models. Midi Health takes a different structural position: it credentialed its clinicians with major commercial insurers so that a covered patient pays only a standard specialist copay, often between $20 and $75 per visit depending on plan design. The company has publicly stated it accepts Aetna, Cigna, United Healthcare, Blue Cross Blue Shield plans, and several others, though coverage must be verified individually before scheduling.

This model matters clinically because cost is a documented barrier to menopause care. A 2023 survey published in Menopause found that fewer than 25% of U.S. Women experiencing vasomotor symptoms reported receiving any prescription treatment, with cost and access cited as primary obstacles [1]. Reducing visit cost through insurance billing directly addresses one of those barriers.

Cash-Pay Pathway

Patients without compatible insurance can still access Midi Health through a cash-pay pathway. Initial consultations run approximately $200, with follow-up visits lower. Prescriptions are written to the pharmacy of the patient's choice, and GoodRx or manufacturer copay cards can reduce medication out-of-pocket costs further. Bioidentical estradiol patches, for example, can retail under $30 per month at discount pharmacies with a GoodRx coupon.

Is Midi Health Legit? Assessing Clinical Credibility

The short answer is yes, within the scope of what it claims to do. Midi Health clinicians operate under standard state telehealth prescribing laws, prescribe FDA-approved medications, and document alignment with the Menopause Society's evidence-based guidelines. "legit" requires unpacking what the clinical model actually delivers.

Clinician Credentials and Training

Midi Health staffs nurse practitioners and physicians who complete internal training focused on menopause medicine. The Menopause Society offers a Certified Menopause Practitioner (NCMP) designation, and as of early 2025 fewer than 1,100 such certified clinicians practice in the entire United States [2]. Midi Health does not publish how many of its clinicians hold NCMP credentials, which is a transparency gap worth noting. Patients should ask directly during intake.

Guideline Adherence

The 2023 Menopause Society position statement states that "hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women under age 60 or within 10 years of menopause onset" [3]. Midi Health's publicly described prescribing approach aligns with this recommendation, prescribing transdermal estradiol and oral or vaginal progesterone as first-line options rather than defaulting to oral conjugated equine estrogens, which carry a higher venous thromboembolism risk profile per the 2022 NICE menopause guideline [4].

Transdermal estradiol does not appear to increase VTE risk at standard doses. A large UK case-control study (N=80,396) published in the BMJ found that transdermal estradiol was not associated with increased VTE risk (OR 0.93, 95% CI 0.87 to 1.01), while oral estrogens were (OR 1.58, 95% CI 1.52 to 1.64) [5]. A platform that defaults to transdermal routes is therefore making a defensible, evidence-based prescribing choice.

Regulatory Legitimacy

Midi Health operates under DEA and state medical board licensing for each state it serves. It does not prescribe controlled substances for non-medically indicated purposes. All hormone prescriptions it writes (estradiol, progesterone, testosterone off-label) are either FDA-approved for the indication or represent standard-of-care off-label use. The FDA approved estradiol transdermal systems (various brands) for moderate-to-severe vasomotor symptoms [6], and micronized progesterone (Prometrium) for endometrial protection in women with a uterus [7].

What Does Midi Health Prescribe?

Midi Health's formulary covers the core medications used in evidence-based menopause management. The list is not exhaustive, but it addresses the main treatment categories recognized by the Menopause Society.

Hormone Therapy Options

• Estradiol: transdermal patches (Vivelle-Dot, Climara, generic), gels (Divigel, EstroGel), sprays (Evamist), and vaginal rings (Femring for systemic dosing; Estring for local)
• Progesterone: oral micronized progesterone (Prometrium 100 mg or 200 mg), vaginal progesterone for women who cannot tolerate oral
• Testosterone: off-label, typically anastrozole-compounded or testosterone cypionate at female physiologic doses (5 to 10 mg/week or less). The Menopause Society notes testosterone may improve hypoactive sexual desire disorder in postmenopausal women, though no FDA-approved testosterone product exists specifically for women in the U.S. [8]
• Vaginal estrogen: low-dose vaginal estradiol cream or Vagifem/Yuvafem inserts for genitourinary syndrome of menopause (GSM)

Non-Hormonal Prescriptions

Midi Health also prescribes non-hormonal options, which matter for patients with contraindications to hormone therapy (e.g., hormone-receptor-positive breast cancer history, personal preference). These include:

• Fezolinetant (Veozah): the first FDA-approved non-hormonal medication specifically for vasomotor symptoms, approved May 2023 [9]. It works as a neurokinin 3 (NK3) receptor antagonist targeting the KNDy neuron pathway. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 60% vs. 34% for placebo at 12 weeks [10].
• SSRIs/SNRIs: low-dose paroxetine (Brisdelle, 7.5 mg) is FDA-approved for vasomotor symptoms [11]; escitalopram and venlafaxine are used off-label with supporting evidence.
• Gabapentin: off-label, 300 mg at night has demonstrated modest efficacy for nocturnal hot flashes in randomized trials [12].

What Midi Health Does Not Prescribe

Midi Health does not manage complex oncology-related hormonal decisions, severe psychiatric comorbidities requiring in-person care, or Schedule II controlled substances. Patients with active breast or uterine cancer should see a gynecologic oncologist rather than a telehealth menopause platform.

Midi Health Perimenopause Care: Clinical Scope

Perimenopause begins years before the final menstrual period and is often undertreated because many clinicians lack menopause-specific training. Midi Health's model specifically targets this gap.

Symptom Coverage

The perimenopausal symptom burden is broader than hot flashes alone. The Menopause Society's 2023 statement identifies vasomotor symptoms, sleep disruption, mood changes, cognitive symptoms, genitourinary changes, and sexual dysfunction as all falling within the scope of menopause medicine [3]. Midi Health's intake questionnaire and visit structure address all of these domains, not only hot flashes.

Lab Ordering

Midi Health clinicians can order hormone panels (FSH, estradiol, testosterone, SHBG, thyroid function) through partner labs or instruct patients to use local LabCorp or Quest sites. This matters because FSH above 40 IU/L is a common diagnostic criterion for menopause, though the Menopause Society notes that FSH alone is unreliable during perimenopause due to hormonal fluctuation [3]. A platform that orders appropriate labs rather than relying solely on symptom history demonstrates clinical rigor.

Follow-Up Structure

After an initial prescription, Midi Health schedules follow-up visits at 4 to 12 weeks to assess symptom response, side effects, and dose optimization. This cadence aligns with the Endocrine Society's clinical practice guideline on menopausal hormone therapy, which recommends reassessment at 3 months after initiation [13].

Midi Health vs. Alternatives: A Structured Comparison

Several telehealth platforms compete in the menopause and women's hormonal health space. The table below compares Midi Health against three major alternatives across dimensions that matter to patients.

| Feature | Midi Health | Alloy Health | Evernow | Gennev | |---|---|---|---|---| | Insurance accepted | Yes (major commercial) | No (cash-pay only) | No (cash-pay only) | Limited | | Initial visit cost (cash) | ~$200 | ~$99 (async) | ~$99 | ~$179 | | Synchronous video visits | Yes | Async primary | Yes | Yes | | Formulary breadth | Broad (HRT, non-HRT, testosterone) | Moderate | Moderate | Moderate | | Clinician type | NPs and MDs | NPs and MDs | NPs and MDs | NPs and MDs | | NCMP transparency | Not published | Not published | Not published | Publishes some credentials | | Fezolinetant available | Yes | Not confirmed | Not confirmed | Not confirmed |

Cash-pay costs change frequently. Verify current pricing directly with each platform before scheduling.

The key differentiator for Midi Health is insurance billing. A patient with United Healthcare or Aetna who would pay $200 cash at a competitor may pay only a $40 copay at Midi Health. Over a year of quarterly follow-up visits, that difference reaches $480 in savings, before medication costs.

For patients without compatible insurance, Alloy Health's asynchronous model (questionnaire plus async clinician review) costs less per interaction but provides less real-time clinical depth. Synchronous video visits allow clinicians to observe distress, ask follow-up questions, and build rapport in ways that async questionnaires do not replicate.

Midi Health Reviews: What Patients Report

Published patient reviews for Midi Health skew positive on appointment access speed and clinician attentiveness. Common themes in reviews on Google (4.7/5 average across multiple locations as of early 2025) and Trustpilot include fast scheduling (often within days rather than weeks), clinicians who spend full visit time on symptoms rather than rushing, and satisfaction with receiving prescriptions that prior in-person physicians had refused to write.

Negative reviews cluster around two issues. First, insurance verification delays before the first appointment have frustrated some patients. Second, pharmacy coordination (particularly for compounded testosterone) can require extra patient follow-up. Neither issue is unique to Midi Health, as they reflect systemic problems in U.S. Telehealth pharmacy logistics.

No published peer-reviewed patient satisfaction data specific to Midi Health exists as of the date of this review. HealthRX will update this section when independent outcomes data becomes available.

Clinical Evidence Behind Menopause Telehealth as a Model

The care model itself has evidence support independent of any specific platform. A 2022 systematic review in Maturitas (N=12 studies) found that telehealth delivery of menopause care produced comparable patient satisfaction and symptom improvement scores to in-person delivery, with significantly higher access rates among rural and underserved populations [14]. Telehealth removes geographic barriers that prevent women in non-urban areas from reaching the fewer than 1,100 NCMP-certified practitioners nationwide [2].

The COVID-19 pandemic normalized video visits, and the 2020 DEA flexibilities (partially extended through 2024) allowed telehealth prescribing of non-controlled hormones without an initial in-person visit. Estrogens and progesterone are not scheduled substances, so these visits remain legally straightforward under standard state telehealth laws.

Cost Breakdown: What You Actually Pay at Midi Health

Understanding the full cost requires separating visit fees from medication costs.

Visit Fees

• With insurance: typically $0 to $75 per visit (standard specialist copay)
• Without insurance: approximately $200 for the initial visit; follow-ups typically $100 to $150
• Annual cost for quarterly follow-up (cash, no insurance): approximately $500 to $650 in visit fees alone

Medication Costs

Medication costs depend heavily on what is prescribed and the patient's pharmacy benefits.

• Generic estradiol patch (Vivelle-Dot 0.05 mg, 8-pack, monthly supply): as low as $28 with GoodRx at major chains
• Prometrium 100 mg, 30 capsules: approximately $40 to $80 generic with GoodRx
• Fezolinetant (Veozah) 45 mg, 30 tablets: approximately $550 per month retail, though Astellas offers a patient assistance program and many commercial plans cover it [9]
• Low-dose vaginal estradiol (Vagifem 10 mcg, 24 inserts): approximately $80 to $130 generic

For a patient on transdermal estradiol plus oral progesterone with insurance covering visits, total annual cost could fall under $500 including medications. Without insurance and on fezolinetant, annual costs could exceed $7,000.

Who Should and Should Not Use Midi Health

Appropriate Candidates

Women aged 35 and older experiencing perimenopausal or menopausal symptoms who have no active hormone-sensitive cancers, no prior pulmonary embolism or unexplained clotting disorders, and no current complex psychiatric diagnoses requiring in-person coordination are reasonable candidates for a Midi Health consultation. Women who have been dismissed by primary care physicians when seeking hormone therapy discussion are particularly likely to benefit from a specialist-focused platform.

Situations Requiring a Different Level of Care

Women with a personal history of breast cancer should consult a breast oncologist or gynecologic oncologist before starting any hormone therapy, including vaginal estrogen. The 2023 American Cancer Society guideline notes that the data on vaginal estrogen safety in breast cancer survivors remains limited and should be individualized [15]. Women with unexplained uterine bleeding need in-person pelvic evaluation and possible endometrial biopsy before starting estrogen. Midi Health cannot perform pelvic exams or order imaging.